लोड हो रहा है...
Pericardial effusion under nivolumab: case-reports and review of the literature
BACKGROUND: Nivolumab, a programmed death-1 (PD-1) inhibitor, is an immune checkpoint inhibitor particularly used in the treatment of malignant melanoma, non-small cell lung cancer and renal cell carcinoma. Immune-related adverse events are frequent under immunotherapies. Cardiotoxic side effects, i...
में बचाया:
| में प्रकाशित: | J Immunother Cancer |
|---|---|
| मुख्य लेखकों: | , , , , , , , |
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
BioMed Central
2019
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6798500/ https://ncbi.nlm.nih.gov/pubmed/31627742 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0760-4 |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|